10,000 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Purchased by Compass Capital Corp MA ADV

Compass Capital Corp MA ADV acquired a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 10,000 shares of the company’s stock, valued at approximately $106,000.

Several other institutional investors have also added to or reduced their stakes in the business. Barclays PLC raised its position in shares of ARS Pharmaceuticals by 189.7% in the third quarter. Barclays PLC now owns 111,666 shares of the company’s stock valued at $1,618,000 after purchasing an additional 73,127 shares during the period. First Turn Management LLC purchased a new position in ARS Pharmaceuticals in the 3rd quarter valued at approximately $8,603,000. Royce & Associates LP raised its holdings in ARS Pharmaceuticals by 7.1% during the 3rd quarter. Royce & Associates LP now owns 691,455 shares of the company’s stock valued at $10,026,000 after acquiring an additional 45,755 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in shares of ARS Pharmaceuticals during the third quarter worth $2,584,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of ARS Pharmaceuticals by 766.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock worth $3,401,000 after acquiring an additional 207,456 shares during the period. 68.16% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Laura Shawver sold 14,772 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $13.75, for a total transaction of $203,115.00. Following the sale, the director now owns 210,346 shares in the company, valued at approximately $2,892,257.50. This trade represents a 6.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Justin Chakma sold 25,000 shares of ARS Pharmaceuticals stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $14.39, for a total transaction of $359,750.00. Following the sale, the insider now directly owns 136,380 shares of the company’s stock, valued at $1,962,508.20. This represents a 15.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 617,102 shares of company stock worth $7,935,840. Insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Stock Down 4.6 %

NASDAQ:SPRY opened at $11.24 on Friday. The stock has a market cap of $1.09 billion, a P/E ratio of -22.04 and a beta of 0.99. The business’s 50-day moving average price is $12.02 and its two-hundred day moving average price is $13.22. ARS Pharmaceuticals, Inc. has a twelve month low of $7.50 and a twelve month high of $18.51.

Analyst Ratings Changes

SPRY has been the topic of a number of analyst reports. William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a research note on Friday. Raymond James lifted their target price on ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 14th. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 price target on the stock. Finally, Leerink Partners boosted their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ARS Pharmaceuticals currently has an average rating of “Buy” and an average target price of $28.80.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.